Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714232 · ClinicalTrials.gov registry record · NA
Evaluation of Blood Glucose Meter Systems
A NA study, sponsored by Ascensia Diabetes Care.
- Completed
- Registry status
- NA
- Development phase
- 106
- Enrollment target
NCT01714232: Completed NA study, sponsored by Ascensia Diabetes Care.
NCT01714232 is a NA study that has completed, run by Ascensia Diabetes Care. The registered enrollment target is 106 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01714232, a NA study, has completed, sponsored by Ascensia Diabetes Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the performance of a Bayer Blood Glucose Monitoring System (BGMS) and four additional Blood Glucose Monitoring Systems (BGMS) from other manufacturers. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Primary Outcome
Using the overall Blood Glucose (BG) range (27 to 460 mg/dL), the Mean Absolute Relative Differences (MARD) between the BGM System readings and the YSI laboratory reference values were compared. MARD was calculated from the sum of all \|(BG meter)-(BG reference)\|/(BG reference) assessments, divided by the number of assessments, then multiplied by 100(%). Each evaluable sample was tested on all 5 BGMS, thus the same number of BG test results was analyzed for each BGMS intervention. Lower MARD va
Interventions
- DEVICE Contour® PLUS BGMS
- DEVICE OneTouch® SelectSimple™ BGMS
- DEVICE Accu-Chek® Performa BGMS
- DEVICE Accu-Chek® Active BGMS
- DEVICE Freestyle Freedom® BGMS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2012-10 |
| Est. Completion | 2012-11 |
| Phase | NA |
What the finished NCT01714232 record still lists
NCT01714232 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 5 interventions - of which Contour® PLUS BGMS is the first listed.
NCT01714232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01714232 about?
NCT01714232 is a clinical study titled "Evaluation of Blood Glucose Meter Systems". The purpose of this study was to evaluate the performance of a Bayer Blood Glucose Monitoring System (BGMS) and four additional Blood Glucose Monitoring Systems (BGMS) from other manufacturers. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method...
What is the current status of trial NCT01714232?
This trial is currently completed. It is a NA study. The enrollment target is 106 participants. The study started on 2012-10. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01714232?
The interventions under investigation include: Contour® PLUS BGMS (DEVICE), OneTouch® SelectSimple™ BGMS (DEVICE), Accu-Chek® Performa BGMS (DEVICE), Accu-Chek® Active BGMS (DEVICE), Freestyle Freedom® BGMS (DEVICE).
Who is sponsoring clinical trial NCT01714232?
This trial is sponsored by Ascensia Diabetes Care, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01714232's enrollment target sits among peer trials
106 830th of 2000 higher than 1,167 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia